



UK Interdisciplinary  
Breast Cancer  
Symposium 2020

**MONDAY 27<sup>th</sup> – TUESDAY 28<sup>th</sup> JANUARY**  
INTERNATIONAL CONVENTION CENTRE, BIRMINGHAM

**Registration for the UKIBCS 2020 is now open**

The pre-early bird registration fee rate ends on 1<sup>st</sup> October 2019.  
Registration fees can be viewed [here](#)

[Click here to register](#)

Abstracts will be accepted for oral and poster presentations

**Abstract Submission Deadline: 1<sup>st</sup> October, midnight**

[Click here to submit an abstract](#)

**The full meeting programme will be circulated in September.  
The programme will include:**

Key Note Lectures on:

Personalised breast radiation therapy – are we there yet?

***Professor Philip Poortmans, France***

Treatment dependent breast tumour evolution

***Professor Matthew Ellis, USA***

Successes, disappointments and the future for clinical trials in primary breast cancer

***Dr Martine Piccart, Belgium***

De-escalating surgery for breast cancer

***Dr Monica Morrow, USA***

De-escalation of medical adjuvant therapy

***Dr Eric Winer, USA***

Genetics and breast cancer risk

***Dr Judy Garber, USA***

**breast cancer  
now**

**ABS**  
ASSOCIATION OF  
BREAST SURGERY

**British Breast Group**



**UKBCG**  
UK Breast Cancer Group

**BSBR**  
BRITISH SOCIETY OF  
BREAST RADIOLOGY

**The Royal College of Pathologists**  
Pathology: the science behind the cure

**NCRI**  
National Cancer  
Research Institute

**RCR**  
The Royal College of Radiologists

## **SYMPOSIA**

### **Highlights of 2019**

Basic

Translational

Primary disease

Advanced disease

Ingunn Holen, UK  
Nick Turner, UK  
Andrew Wardley, UK  
David Miles, UK

### **Demystifying partial breast irradiation**

Why and how to do it?

Does it work and who should have it?

Is less really less?

Anna Kirby, UK  
Charlotte Coles, UK  
Philip Poortmans, France

### **Phenotypic and genotypic heterogeneity**

Genomics of invasive lobular breast cancer

Genomic landscape of breast cancer metastasis and relapse

Molecular evolution of lymph-node spread in early breast cancer

- a surgeon's interest

Christine Desmedt, Belgium  
Adrian Lee, USA  
Peter Barry, UK

### **Special issues in managing metastatic disease**

Patient specific treatment sequencing in ER+ advanced breast cancer

Whole body MRI in the management of bone metastases

Is treatment of oligometastases curative

Stephen Johnston, UK  
Anwar Padhani, UK  
Andreas Makris, UK

### **Why can't we kill ER+ breast cancer?**

Resistance mechanisms to endocrine therapy

Resistance mechanisms to CDK4/6 inhibition

New prospects for killing ER+ breast cancer cells

Andy Sims, UK  
Ben O'Leary, UK  
Matthew Ellis, UK

### **DCIS - risk estimates and management**

Molecular features of DCIS and invasive breast cancer

Addressing overtreatment of screen detected DCIS; the LORIS trial

Breast cancer-related deaths in DCIS: the Dutch experience

Elly Sawyer, UK  
Matthew Wallis, UK  
Jelle Wesseling, Netherlands

### **Immune therapy**

Treatment response and toxicities in breast cancer

Diagnostic and prognostic aspects

Characterising immune response

Mark Harries, UK  
Roberto Salgado, Belgium  
Raza Ali, UK

### **Big Data in Breast Cancer**

Introduction: the current UK landscape

DCIS in the UK: the Oxford NINBE and Sloane Projects

Twenty five year risks of breast cancer mortality in 500,000 women

Endocrine therapy in the primary care prescription dataset

David Dodwell, UK  
Gurdeep Mannu, UK  
Carolyn Taylor, UK  
Kieran Horgan, UK

### **Managing the axilla**

Can we completely avoid axillary surgery for some breast cancer patients

UK guidelines for management of the axilla post-NAT

Modern role of the radiologist in managing the axilla

Monica Morrow, USA  
Julie Doughty, UK  
Tony Maxwell, UK

### **Late recurrence in ER+ disease**

Late-recurring ER-positive genomic subgroups

Predicting late recurrence, patient, tissue and circulating factors

Preventing late recurrence

Carlos Caldas, UK  
Nick Turner, UK  
Ian Smith, UK

### **Improving breast cancer outcomes by modifying lifestyle**

Obesity and breast cancer risk

Diet before and after a diagnosis of breast cancer and outcome

Exercise

Annie Anderson, UK

Michelle Harvie, UK

Anna Campbell, UK

### **Novel clinical trial design**

Breast cancer trials: Creating designs fit for contemporary questions

Can Bayesian adaptive trials be useful in breast cancer?

Presurgical window studies of novel drugs – what's the end-point?

Judith Bliss, UK

James Wason, UK

Adrian Harris, UK

### **Minimizing mastectomy**

Neoadjuvant chemotherapy

Breast conserving surgery for multifocal tumours

Oncoplastic surgery

Sibylle Loibl, Germany

Mike Dixon, UK

Katy Hogben, UK

### **Prognostic and predictive profiling**

PREDICT vs NPI

Can mRNA replace IHC for ER?

Ki67 - will it ever make it? A report of 10 years' work from the

International Ki67 in Breast Cancer Working Group

Paul Pharoah, UK

Adrian Lee, USA

Mitch Dowsett, UK

### **Special issues for elderly patients**

General presentation taking into account the talks below:

Bridging the Age Gap

Dementia and decision making

KL Cheung, UK

Lynda Wyld, UK

Yasmin Jauhari, UK

### **Breast cancer risk and prevention**

Recent lessons from the WHI study

Chemoprevention of breast cancer – where have we got to?

Low-dose tamoxifen for breast cancer prevention

Rowan Chlebowski, USA

Jack Cuzick, UK

Andrea Decensi, Italy

### **Special issues in managing young patients**

Choosing endocrine treatment

Managing fertility in breast cancer

Pregnancy after breast cancer

Dan Rea, UK

Melanie Davies, UK

Sibylle Loibl, Germany

### **Modelling breast cancer - moving closer to the clinic**

Hormones and breast cancer- why models matter

A new 3D model for breast cancer - alternative to xenografts and PDX

The challenges of measuring the response to immunotherapies in vivo

Cathrin Brisken, Switzerland

Gillian Farnie, UK

Jonas Nilsson, Sweden

### **Translating new therapeutic opportunities**

Targeting CDK7 in ER+ breast cancer

Androgen receptor agonists for AR+ disease

Rationale and progress in targeting FOXA1

Simak Ali, UK

Carlo Palmieri, UK

Jason Carroll, UK

### **Managing the side-effects of endocrine therapy**

Managing the sexual impact of endocrine therapy

Hot flushes

Impact on treatment adherence

Isabel White, UK

Debbie Fenlon, UK

Mike Dixon, UK

### **Other sessions include:**

#### **Young clinical leaders**

#### **Trials in Progress**

#### **The new MDMT**

#### **Selected free communications**